OPTUS Pharmaceutical (A131030) Stock Overview
Provides ophthalmic solutions in South Korea. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 3/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
A131030 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
OPTUS Pharmaceutical Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩7,580.00 |
| 52 Week High | ₩8,960.00 |
| 52 Week Low | ₩5,610.00 |
| Beta | 0.37 |
| 1 Month Change | 9.38% |
| 3 Month Change | 11.31% |
| 1 Year Change | 18.62% |
| 3 Year Change | 18.81% |
| 5 Year Change | -2.32% |
| Change since IPO | 42.21% |
Recent News & Updates
Returns On Capital At OPTUS Pharmaceutical (KOSDAQ:131030) Paint A Concerning Picture
Sep 26
OPTUS Pharmaceutical Co., Ltd.'s (KOSDAQ:131030) Shares Climb 34% But Its Business Is Yet to Catch Up
Jul 23Recent updates
Returns On Capital At OPTUS Pharmaceutical (KOSDAQ:131030) Paint A Concerning Picture
Sep 26OPTUS Pharmaceutical Co., Ltd.'s (KOSDAQ:131030) Shares Climb 34% But Its Business Is Yet to Catch Up
Jul 23Beyond Lackluster Earnings: Potential Concerns For OPTUS Pharmaceutical's (KOSDAQ:131030) Shareholders
May 28Capital Allocation Trends At OPTUS Pharmaceutical (KOSDAQ:131030) Aren't Ideal
Mar 31OPTUS Pharmaceutical Co., Ltd.'s (KOSDAQ:131030) 30% Share Price Surge Not Quite Adding Up
Jan 08OPTUS Pharmaceutical's (KOSDAQ:131030) Profits Appear To Have Quality Issues
Nov 26Benign Growth For OPTUS Pharmaceutical Co., Ltd. (KOSDAQ:131030) Underpins Stock's 25% Plummet
Nov 14Investors Could Be Concerned With OPTUS Pharmaceutical's (KOSDAQ:131030) Returns On Capital
Nov 13Capital Allocation Trends At OPTUS Pharmaceutical (KOSDAQ:131030) Aren't Ideal
Aug 07There's Reason For Concern Over OPTUS Pharmaceutical Co., Ltd.'s (KOSDAQ:131030) Massive 28% Price Jump
Jun 27There's No Escaping OPTUS Pharmaceutical Co., Ltd.'s (KOSDAQ:131030) Muted Earnings Despite A 43% Share Price Rise
Mar 25OPTUS Pharmaceutical's (KOSDAQ:131030) Earnings Are Of Questionable Quality
Mar 13The Returns On Capital At DHP Korea (KOSDAQ:131030) Don't Inspire Confidence
Apr 05DHP Korea's (KOSDAQ:131030) Problems Go Beyond Weak Profit
Mar 09DHP Korea Co., Ltd.'s (KOSDAQ:131030) Stock Has Been Sliding But Fundamentals Look Strong: Is The Market Wrong?
Feb 10
How Much Did DHP Korea's(KOSDAQ:131030) Shareholders Earn From Share Price Movements Over The Last Five Years?
Jan 12Should We Be Excited About The Trends Of Returns At DHP Korea (KOSDAQ:131030)?
Dec 08Shareholder Returns
| A131030 | KR Medical Equipment | KR Market | |
|---|---|---|---|
| 7D | 5.4% | 1.8% | 3.3% |
| 1Y | 18.6% | -6.5% | 89.2% |
Return vs Industry: A131030 exceeded the KR Medical Equipment industry which returned -6.5% over the past year.
Return vs Market: A131030 underperformed the KR Market which returned 89.2% over the past year.
Price Volatility
| A131030 volatility | |
|---|---|
| A131030 Average Weekly Movement | 4.7% |
| Medical Equipment Industry Average Movement | 6.3% |
| Market Average Movement | 5.9% |
| 10% most volatile stocks in KR Market | 12.2% |
| 10% least volatile stocks in KR Market | 2.7% |
Stable Share Price: A131030 has not had significant price volatility in the past 3 months compared to the KR market.
Volatility Over Time: A131030's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2002 | n/a | Dong-Hwa Han | www.optuspharm.com |
OPTUS Pharmaceutical Co., Ltd. provides ophthalmic solutions in South Korea. The company offers dry eye preparation, antibiotics, anti-allergic preparation, steroids preparation, glaucoma treatment, and retinopathy treatment products. It also provides ETC, OTC, cosmetics, healthcare, and other products, as well as single-dose unit eye drops and eye care products under OEU& brand name.
OPTUS Pharmaceutical Co., Ltd. Fundamentals Summary
| A131030 fundamental statistics | |
|---|---|
| Market cap | ₩133.76b |
| Earnings (TTM) | ₩11.18b |
| Revenue (TTM) | ₩87.58b |
Is A131030 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A131030 income statement (TTM) | |
|---|---|
| Revenue | ₩87.58b |
| Cost of Revenue | ₩38.71b |
| Gross Profit | ₩48.87b |
| Other Expenses | ₩37.68b |
| Earnings | ₩11.18b |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 633.76 |
| Gross Margin | 55.80% |
| Net Profit Margin | 12.77% |
| Debt/Equity Ratio | 0% |
How did A131030 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/01/23 18:32 |
| End of Day Share Price | 2026/01/23 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
OPTUS Pharmaceutical Co., Ltd. is covered by 3 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Yang Ju Park | Daishin Securities Co. Ltd. |
| Wan Ku | iM Securities |
| Dongguen Kang | Yuanta Securities Korea Co., Ltd. |